- Current GI-MAP Turnaround Time: 7–10 Business Days

The Importance of Dysbiosis in the Upper GI Tract

The term “dysbiosis” denotes imbalances or disruptions in the microbiome that are thought to contribute to a long and growing list of chronic diseases and conditions. To date, microbiome research has largely focused on dysbiosis in the colon, which is typically assessed via stool sampling.

Recent research indicates that the oral microbiome may also be involved in certain disease processes. Dysbiosis in other areas of the gastrointestinal tract has been less extensively explored, but emerging evidence indicates that dysbiosis in these areas may also have important impacts on health.

In this presentation, we will explore what’s known about dysbiosis in the upper GI tract (especially in the stomach and upper small intestine), and how advanced DNA-based stool testing may provide important clinical insights.


Tom Fabian, PhD, CNTP

Presented by Tom Fabian, PhD, CNTP

Tom is a clinical laboratory consultant, translational science expert, functional nutrition practitioner, educator, and speaker. He is a former biomedical research scientist with deep expertise in the role of the human microbiome in health, chronic disease, and aging. As a leading expert in translational applications of microbiome research in functional medicine and integrative health settings, Tom’s primary focus is on providing educational resources and consulting services for practitioners, and consulting and advisory services for clinical testing laboratories. On a limited basis, he also works with individual clients to improve gastrointestinal health and optimize healthspan.